louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05360303: Electromyography in Thoracic Outlet Syndrome
Official title: Interest of Electroneuromyography in the Diagnosis of Thoracic Outlet Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thoracic Outlet Syndrome
Keywords: Thoracic outlet syndrome
electromyography
neurogenic
rehabilitation
diagnosis
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2022-05-04
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a thoracic outlet syndrome who will be included during their usual rehabilitation management. They will benefit from the usual Electromyography of stimulodetection with surface electrodes at the beginning of the management. The same examination will be performed at the end of the treatment to evaluate the impact of the rehabilitation on the electrophysiological results and to orientate, if necessary, towards a potential surgery.

Brief summary: Record the ENMG data carried out systematically in patients treated by rehabilitation for thoracic outlet syndrome in order to assess their characteristics and judge the relevance of these data in the context of the diagnosis and their possible modifications following the rehabilitation treatment.


Eligibility criteria: Inclusion Criteria:

* Inpatient rehabilitation for thoracic outlet syndrome
* Patients' agreement

Exclusion Criteria:

* \< 18 years old
* Not able to consent
* Pregnancy
* Musculoskeletal disorders of the upper limbs
* Acute cardiac, pulmonary, metabolic or neurological diseases

Primary outcomes:
measure: Evaluation of the presence of ENMG abnormality and in particular on the medial cutaneous nerve of the forearm of patients with a clinical diagnosis of TOS
timeFrame: 0 Month
Secondary outcomes:
measure: Evaluation of ENMG changes following rehabilitation treatment of patients
timeFrame: 1 Month
measure: Evaluation of ENMG changes following rehabilitation treatment of patients
timeFrame: 1 Month
measure: Evaluation of ENMG changes following rehabilitation treatment of patients
timeFrame: 1 Month
Other outcomes:
Locations:
city: Nantes
country: France
facility: Department of Physical Medicine and Locomotive Rehabilitation (Nantes University Hospital)
Study officials:
References:
Clinical trial NCT06513403: Preliminary Research Using Artificial Intelligence Technology to Identify Differences in Facial Expressions Between Healthy People, Patients With Cognitive Decline, and Patients With Dementia
Official title: Preliminary Study Using Artificial Intelligence Technology to Identify Differences in Facial Expressions Between Healthy People, Patients With Cognitive Decline, and Patients With Dementia
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Artificial Intelligence Technology
Cognitive Decline
Dementia
Identify
Facial Expressions
Keywords: artificial intelligence technology
cognitive decline
dementia
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 60
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Normal cognition group (Health): 20 participants
* Mild cognitive impairment group (MCI): 20 participants
* Dementia group: 20 participants

Brief summary: Through artificial intelligence technology, we have conducted a preliminary study aimed at identifying differences in facial expressions among healthy individuals, patients with cognitive decline, and dementia patients. This research offers a novel method and tool for dementia screening, contributing to effective strategies for dementia prevention in our country. By utilizing this approach, we can effectively delay the onset of disability, promote healthy aging among our elderly population, reduce the caregiving burden on individuals, families, and society, and lower medical expenses.


Eligibility criteria: Inclusion Criteria:

Age between 50 and 75 years.

* Experimental group:
* MCI group: CDR score of 0.5 or MMSE score between 20-25 (mild/early stage).
* Dementia group: CDR score greater than 1 or MMSE score between 10-19 (moderate/middle stage).
* Control group:
* Health group: MMSE score of 26 or above.
* Participants must be conscious and able to follow instructions.

Primary outcomes:
measure: Facial Expression Test
timeFrame: 2024/8/1-2025/10/31
Secondary outcomes:
Other outcomes:
Locations:
city: Hsinchu
country: Taiwan
facility: NTUH
Study officials:
References:
Clinical trial NCT03567603: Sound Processing Changes in Babies With Opioid Exposure
Official title: A Comparison of Mismatch Negativity Waveform Differences in Opioid-exposed and Non-exposed Neonates.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neonatal Abstinence Syndrome
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2018-06-26
Enrollment: 37
Sex: ALL
Maximum age (years): 20
Standard ages: CHILD
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Investigators with routine access to infant and maternal records will identify subjects based on review of patient charts upon admission to the NICU or nursery.

Brief summary: The purpose of this study is to identify problems with interpreting sounds in babies that have been exposed to opioids prior to birth. Being able to identify these issues in infancy may allow us to find children who may have problems with language learning later in life so that we can try to minimize these.

Detailed description: This is a single center prospective study of neonates \>36 weeks' gestation prenatally exposed to psychoactive substances and gestationally age-matched controls. Evoked response potentials on EEG in response to auditory oddball paradigms will be compared between cohorts. Analyses will try to identify differences in auditory processing using ANOVAs to compare the mismatch negativity measures, amplitudes and latencies as a function of study group.

Eligibility criteria: Inclusion Criteria:

* Gestational age ≥ 36 weeks, confirmation of dates via ultrasound or last menstrual period
* Prenatal opioid exposure ("exposed"), confirmed via admitted use or newborn drug screen; no prenatal opioid exposure ("control") by maternal report or testing
* All races, ethnicities, sexes to be included
* Informed permission form signed by mother

Exclusion Criteria:

* Birth weight ≤ 3rd percentile or ≥ 97th percentile for gestational age
* Have comorbid medical disorders including; those associated with sensorineural hearing loss, significant congenital anomalies, congenital heart disease, known brain injury/malformations
* Infants requiring mechanical ventilation
* Infants requiring continuous sedation

Primary outcomes:
measure: Percent with neonates with auditory cortical processing deficiencies
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
Study officials:
affiliation: University of Rochester
name: Ronnie Guillet, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04637243: Outcomes From Treatment Liver and Bile Duct Diseases
Official title: Evaluation of Outcomes From Treatment of Benign or Malignant Liver and Bile Duct Diseases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Benign or Malignant Liver and Bile Duct Disease
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2020-11-19
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in Richardson, T.X.

Brief summary: It is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. Our goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity.

The main aim of this study is to evaluate and compare the outcomes from our multiple treatments of benign or malignant liver and bile duct diseases.

Detailed description: The study will be a retrospective chart review of patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in Richardson, T.X. We plan to conduct an analysis of patients meeting the inclusion criteria form 2005 to present (up to the day before this study receives IRB approval). Charts will also be reviewed by the PI. Sub-I, Fellows, Office Staff, Clinical Research Coordinator who are delegated to do so by the PI. Data will be obtained from a national database. Data will be analyzed primarily by the study conductors.

Eligibility criteria: Inclusion Criteria:

* All patients diagnosed and treated for liver and bile duct disease benign or malignant from 2005 to present (up to the day before this study receives IRB approval)
* Age \> 18 years

Exclusion Criteria:

* Patients that are not diagnosed with or treated for liver and bile duct disease
* Age \< 18 years

Primary outcomes:
measure: Mortality from Treatment of Benign or Malignant Liver and Bile Duct Diseases
timeFrame: 2005 to 2019
measure: Morbidity from Treatment of Benign or Malignant Liver and Bile Duct Diseases
timeFrame: 2005 to 2019
Secondary outcomes:
Other outcomes:
Locations:
city: Richardson
country: United States
facility: Methodist Richardson Medical Center
state: Texas
Study officials:
affiliation: Trinity Surgical Consultants, Methodist Richardson Medical Center
name: Dhiresh Jeyarajah, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03026543: Effect of Pulmonary Recruitment Maneuver (PRM) on Pain and Nausea After Laparoscopic Cholecystectomy
Official title: A Prospective, Blinded, Randomized Clinical Trial Investigating the Effect on Postoperative Pain and Nausea, When Performing a Ventilator-piloted PRM at the End of Laparoscopic Cholecystectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Postoperative
Postoperative Nausea and Vomiting
Lead sponsor: Region Östergötland
Sponsor class: OTHER
First posted: 2017-01-20
Enrollment: 260
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This prospective, blinded, randomized clinical trial investigates the effect on postoperative pain and nausea, when performing a ventilator-piloted PRM at the end of a laparoscopic cholecystectomy.


Eligibility criteria: Inclusion Criteria:

* elective laparoscopic cholecystectomy
* American Society of Anesthesiologists (ASA) physical status classification I-II (with the exception of body mass index over 35 kg/m2)
* written consent

Exclusion Criteria:

* conversion to open surgery
* Clavien-Dindo grade ≥ II

Primary outcomes:
measure: Change in postoperative pain assessed with a numeric rating scale
timeFrame: 4, 12, 24, 36 and 48 hours after surgery
Secondary outcomes:
measure: Change in postoperative nausea assessed with a Questionnaire
timeFrame: 4, 12, 24, 36 and 48 hours after surgery
Other outcomes:
Locations:
city: Norrkoping
country: Sweden
facility: Vrinnevi Hospital
state: Östergötland
Study officials:
affiliation: Vrinnevi Hospital, Norrköping, Sweden
name: Ebba Kihlstedt Pasquier, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Vrinnevi Hospital, Norrköping, Sweden
name: Ellen Andersson, MD, PhD
role: STUDY_CHAIR
References:
citation: Kihlstedt Pasquier E, Andersson E. Pulmonary Recruitment Maneuver Reduces Shoulder Pain and Nausea After Laparoscopic Cholecystectomy: A Randomized Controlled Trial. World J Surg. 2021 Dec;45(12):3575-3583. doi: 10.1007/s00268-021-06262-6. Epub 2021 Sep 5.
Clinical trial NCT00037843: Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening
Official title: Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Adrenal Gland Diseases
Adrenal Gland Neoplasms
Keywords: adrenal diseases
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: University of Michigan
First posted: 2002-05-24
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is a clinical research study using I-131 Iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging devices. These images are used in diagnosing a variety of adrenal abnormalities.Prior to the injection of I-131 Iodocholesterol, the patient will receive perchlorate capsules to block any uptake of I-131 by the thyroid gland if this is deemed important. The patient will continue to take these capsules throughout the period of imaging, which may last up to 1 week. The injection of I-131 Iodocholesterol will be given into a vein and the patient will return for images on at least 1 and possibly 2 occasions between 3-7 days after injection. If the case requires it, the patient may also be given a steroid in tablet form, dexamethasone, to take orally prior to and after the injection to suppress normal adrenal function so that the abnormal tissues can be more easily detected.


Eligibility criteria: Adults with suspected adrenal disease, such as adrenal adenoma, carcinoma, hyperplasia, or Addison's Disease.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Texas M.D. Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Donald A. Podoloff, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06533943: Blue-green Space Physical Activity: the "Parco Del Mare" Study
Official title: Engaging in Physical Activity Carried Out in a Blue-green Space to Improve Health, Quality of Life and Physical Performance Among the Population: the "Parco Del Mare" Study Protocol
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy Adults
Natural Outdoor Environment
Health Promotion
Keywords: blue-green space setting
physical activity intervention
outdoor exercise
public health
Lead sponsor: Università degli Studi 'G. d'Annunzio' Chieti e Pescara
Sponsor class: OTHER
First posted: 2024-08-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study protocol, describe the innovative study intervention which will be performed in a green-blue space in Italy in order to investigate on the improvements in wellbeing following participation in the study. This will be significant because it will provide evidence on the effectiveness of the supervised physical activities carried out in green-blue space in improving health, quality of life, physical performance, anthropometric outcomes and physiological parameters in adults, indicating the reasonableness for public health authorities to developing such activities.

Detailed description: The aim of the "Parco del Mare" pilot study is to evaluate the feasibility and the effects of a moderate-intensity exercise program carried out in a green-blue space, on health outcomes such as quality of life and physical performance. Healthy adults with no contraindication to practice physical activity will be recruited and divided into two groups: the experimental group involved in the exercise sessions performed twice a week for 6-months, while the control group received no intervention. Validated tests and questionnaires will be used to detect health parameters at baseline (T0) and follow-up (T1). The investigators expected the intervention carried out in the Parco del Mare setting to be feasible and effective in improving health parameters, quality of life and physical performance in healthy adults.

Eligibility criteria: Inclusion Criteria:

* Adult population aged \>18 years old
* Resident in Rimini

Exclusion Criteria:

* Any alterations in communication skills and/or sensory functions so severe as to make it impossible to understand and/or execute the instructions given by the trainer (dementia, aphasia, blindness, deafness)

Primary outcomes:
measure: 12-Item Short Form Survey (SF-12)
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Rimini
country: Italy
facility: Parco del Mare
Study officials:
References:
Clinical trial NCT00280943: Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities
Official title: Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities Written for FDA Approved Medications for Osteoporosis Treatment.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hip Fractures
Osteoporosis
Keywords: All NC LTC facilities having ten residents with a hip fracture or osteoporosis on the MDS will be invited to participate in the trial
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2006-01-24
Enrollment: 64
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Osteoporotic fractures of the hip are a major cause of admission to long-term care facilities. Such fractures put patients at high risk for further fractures, pain and disability. Current data show that many patients in long-term care facilities do not receive FDA medications for their osteoporosis. This trial will test whether a multi-model intervention (which provides feedback about provider use of osteoporosis medications, information about osteoporosis, and currently approved osteoporosis medications)directed at physicians, other health care providers, and nurses will improve the number of prescriptions written for FDA approved medications for osteoporosis treatment.


Eligibility criteria: Inclusion Criteria:

Any North Carolina long-term care facility with ten residents who had had a hip fracture or osteoporosis diagnosis

Primary outcomes:
measure: Number of new prescriptions for FDA-Approved osteoporosis medications.
Secondary outcomes:
measure: Secondary Outcome Measures: Changes in number of bone mineral density test ordered, change in the number of hip protectors issued, change in the number of prescriptions for calcium and vitamin D, changes in the rate of new osteoporotic fractures.
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Kenneth W Lyles, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Duke University
name: Cathleen S. Colon-Emeric, MD, MHSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Colon-Emeric CS, Lyles KW, House P, Levine DA, Schenck AP, Allison J, Gorospe J, Fermazin M, Oliver K, Curtis JR, Weissman N, Xie A, Saag KG. Randomized trial to improve fracture prevention in nursing home residents. Am J Med. 2007 Oct;120(10):886-92. doi: 10.1016/j.amjmed.2007.04.020.
Clinical trial NCT01523743: Quality of Life Intermittent Catheter Study
Official title: Quality of Life Intermittent Catheter Study - A Prospective, Randomized, Cross-over, Multicenter Study Comparing Quality of Life Using Compact Versus Standard Urinary Intermittent Catheters
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Neurogenic Bladder Dysfunction Nos
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2012-02-01
Enrollment: 125
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to compare compact intermittent catheters with standard coated intermittent catheters with regard to quality of life, using the Intermittent Self-Catheterisation Quality of life Measure.


Eligibility criteria: Inclusion Criteria:

* Is at least 18 years of age
* Has given written informed consent
* Has neurogenic bladder dysfunction
* Has used coated intermittent catheter as primarily bladder emptying method for at least 6 months
* Is able to self-catheterise
* Is able to use SpeediCath® compact catheters
* If spinal cord injury subject, injury must have occurred more than 12 months ago
* Covered by Social security system

Exclusion Criteria:

* Has used SpeediCath® compact catheters (not including screening for this investigation)
* Is admitted to rehabilitation centre
* Subjects using primarily catheter sets
* Is pregnant or breast-feeding

Primary outcomes:
measure: Quality of Life (0-100 Point)
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Charlottenlund
country: Denmark
facility: PrivatHospitalet Danmark, privat hospital,
city: Copenhagen
country: Denmark
facility: Rigshospitalet, Urology clinic,
city: Vejle
country: Denmark
facility: CCBR Vejle, Clinical research site,
city: Paris
country: France
facility: Hôpital Tenon, Neuro-Urology and perineal explorations department,
state: Cedex 20
city: Garches
country: France
facility: Hôpital Raymond Poincaré, Urology clinic
city: Hyères cedex
country: France
facility: Hôpital Léon Berard, Rehabilitation clinic,
city: Saint Genis Laval
country: France
facility: Hôpital Henry Gabrielle, Urology clinic,
city: Heidelberg
country: Germany
facility: University Heidelberg, Neuro-Urology clinic,
city: Trondheim
country: Norway
facility: St. Olavs Hospital HF, Neurologi clinic,
city: Gävle
country: Sweden
facility: Gävle sjukhus, Urology clinic,
city: Stockholm
country: Sweden
facility: Rehab Station Stockholm,
Study officials:
affiliation: Hôpital Raymond poincarè, Service d'Urologie, Garches, France
name: Emmanuel Chartier-Kastler, Proff
role: PRINCIPAL_INVESTIGATOR
References:
citation: Prieto JA, Murphy CL, Stewart F, Fader M. Intermittent catheter techniques, strategies and designs for managing long-term bladder conditions. Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD006008. doi: 10.1002/14651858.CD006008.pub5.